Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit

Haemophilia. 2021 Jul;27(4):e567-e570. doi: 10.1111/hae.14326. Epub 2021 Apr 29.

Authors

Donata Urbaniak-Kujda¹, Monika Maria Biernat¹, Tomasz Skalec², Jagoda Jacków-Nowicka³, Jerzy Windyga⁴, Tomasz Wróbel¹

Affiliations

¹ Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
² Department of Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Wrocław, Poland.
³ Department of Radiology, Wroclaw Medical University, Wrocław, Poland.
⁴ Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Bispecific / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Anticoagulants / therapeutic use
COVID-19 / complications*
COVID-19 / diagnosis
COVID-19 / therapy
Disease Management
Hemophilia A / complications*
Hemophilia A / therapy
Hemorrhage / prevention & control
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Intensive Care Units
Male
SARS-CoV-2 / isolation & purification
Thrombosis / prevention & control
Treatment Outcome

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Anticoagulants
Heparin, Low-Molecular-Weight
emicizumab